Articles from M2 Pharma (March 21, 2017)

Title	Author	Type	Words
Allergan plc passes US FDA approval for JUVA[per mille]DERM VOLLURE XC for correction of facial wrinkles and folds in adults.			278
Americans Have Substantial Differences in Drug-Metabolising Gene, Study Finds.			288
Apexigen Receives Clinical Development Milestone Payment.			232
Argenx and Broteio announce new collaborative project.			274
Arix Bioscience, LDC and University of Leeds to collaborate on development of novel treatments for metabolic diseases.			254
Champions Oncology Plans to Open New Lab Facility in Maryland, USA.			161
Circassia Pharmaceuticals to pay USD230m for US commercial rights for Tudorza and Duaklir.			183
CytoSorbents Forms South Africa Partnership with Dr. Reddy's Laboratories.			284
Eurofins investing millions in growing UK capacity.			264
Eyevensys appoints Dr Garth Cumberlidge as its new chairman.			290
Forecasters predict APAC non-small cell lung cancer market will double.			297
General Catalyst, Kinnevik Co-Lead USD 52.5m Investment in Livongo Health.			249
Global Biostimulants Market to Grow at a CAGR of 11.2% through 2022, Research and Markets Forecasts.			222
IBM Watson Health to Integrate MedyMatch Technology into Cognitive Imaging Offerings.			434
IDx and IBM Watson Health to Advance Eye Health in Five-Year Alliance.			538
La Jolla Pharmaceutical expects USD100m from public offering of common stock.			174
Mallinckrodt divests USD203m Intrathecal Therapy business.			163
MDxHealth SA and Lab21 enter new distribution agreement for SelectMDx, a prostate cancer test.			215
Meda EpiPen batch recalled in Denmark following reports of defects.			259
Mylan wins US FDA's tentative approval for TLE400 for HIV/AIDS under PEPFAR.			239
New class of gene-silencing drug halves cholesterol in CVD patients.			331
Nichols Named Chief Medical Officer at The Leukemia and Lymphoma Society.			518
Nigeria's Swipha acquired by Biogaran.			199
Novartis hails success of its psoriasis treatment drug Cosentyx.			289
Novartis reveals results of new post-hoc analysis of Entresto.		Financial report	152
Oncolytics Biotech Teams with Myeloma UK, Celgene.			474
Oxford BioDynamics and five partners collaborate for rheumatoid arthritis triggers study.			183
Palatin Technologies announces USPTO Notice of Allowance for Bremelanotide Methods for treating hypoactive sexual desire disorder.			232
Phosphorus Launches Genetic Tests for Inherited Cardiology Diseases Associated with Sudden Death.			261
Protein in spider venom could prevent brain damage caused by stroke.			647
Redx Pharma announces board changes and cancer treatment progress in full-year results.		Financial report	279
Rosetta Genomics expects patent for its unique RosettaGX Reveal assay from USPTO.			233
VolitionRx Limited reports launch of new subsidiary Volition America Inc.			192
Women's Health Rehabilitation Products Market to Reach USD 4.4bn by 2025, Grand View Research Forecasts.			288